Latest & greatest articles for irritable bowel syndrome

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on irritable bowel syndrome or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on irritable bowel syndrome and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for irritable bowel syndrome

1. Tenapanor (Ibsrela) - irritable bowel syndrome

Tenapanor (Ibsrela) - irritable bowel syndrome Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012

2020 Health Canada - Drug and Health Product Register

2. Bimodal Release Ondansetron Improves Stool Consistency and Symptomatology in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Trial Full Text available with Trip Pro

Bimodal Release Ondansetron Improves Stool Consistency and Symptomatology in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Trial Bimodal Release Ondansetron Improves Stool Consistency and Symptomatology in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced (...) Release Ondansetron Improves Stool Consistency and Symptomatology in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Trial , , , , , , , Affiliations Expand Affiliations 1 RedHill Biopharma, Tel Aviv, Israel. 2 Arkansas Gastroenterology, PA, North Little Rock Arkansas, USA. 3 New Phase Research & Development, Knoxville, Tennessee, USA. 4 Middleburg Consultants, Takoma Park, Maryland, USA. PMID: 32639235 DOI: Item in Clipboard Bimodal Release Ondansetron Improves Stool

2020 EvidenceUpdates

3. beta-Galactooligosaccharide in Conjunction With Low FODMAP Diet Improves Irritable Bowel Syndrome Symptoms but Reduces Fecal Bifidobacteria

beta-Galactooligosaccharide in Conjunction With Low FODMAP Diet Improves Irritable Bowel Syndrome Symptoms but Reduces Fecal Bifidobacteria β-Galactooligosaccharide in Conjunction With Low FODMAP Diet Improves Irritable Bowel Syndrome Symptoms but Reduces Fecal Bifidobacteria - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National (...) RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Am J Gastroenterol Actions . 2020 Jun;115(6):906-915. doi: 10.14309/ajg.0000000000000641. β-Galactooligosaccharide in Conjunction With Low FODMAP Diet Improves Irritable Bowel Syndrome Symptoms but Reduces Fecal Bifidobacteria , , , , , , , , Affiliations Expand Affiliations 1 Department of Nutritional Sciences, King's College London, London, United Kingdom. 2

2020 EvidenceUpdates

4. In irritable bowel syndrome, fecal microbiota transplantation improved symptoms at 3 months. (Abstract)

In irritable bowel syndrome, fecal microbiota transplantation improved symptoms at 3 months. El-Salhy M, Hatlebakk JG, Gilja OH, Bråthen Kristoffersen A, Hausken T. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut. 2020;69:859-67. 31852769.

2020 Annals of Internal Medicine

5. Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome (Abstract)

Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome Peppermint oil is frequently used to treat irritable bowel syndrome (IBS), despite a lack of evidence for efficacy from high-quality controlled trials. We studied the efficacy and safety of small-intestinal-release peppermint oil in patients with IBS and explored the effects of targeted ileocolonic-release peppermint oil.We performed a double-blind trial of 190 patients with IBS (...) (according to Rome IV criteria) at 4 hospitals in The Netherlands from August 2016 through March 2018; 189 patients were included in the intent-to-treat analysis (mean age, 34.0 years; 77.8% female; 57.7% in primary care), and 178 completed the study. Patients were randomly assigned to groups given 182 mg small-intestinal-release peppermint oil, 182 mg ileocolonic-release peppermint oil, or placebo for 8 weeks. The primary endpoint was abdominal pain response, as defined by the US Food and Drug

2020 EvidenceUpdates

6. But I am not Depressed: Antidepressants for Irritable Bowel Syndrome

BE, Harris LA, et al. Am J Gastroenterol. 2019; 114(1):21-39. 2. Ruepert L, Quartero AO, de Wit NJ, et al. Cochrane Database Syst Rev. 2011; (8):CD003460. 3. Ford AC, Quigley EM, Lacy BE, et al. Am J Gastroenterol. 2014; 109(9):1350-65. 4. Moayyedi P, Andrews CN, MacQueen G, et al. J Can Assoc Gastroenterol. 2019; 2(1):6-29. 5. Canadian Digestive Health Foundation. Irritable Bowel Syndrome. Available at: https://cdhf.ca/digestive-disorders/irritable-bowel-syndrome-ibs/what-is-irritable- bowel-syndrome (...) January 20, 2020 But I am not Depressed: Antidepressants for Irritable Bowel Syndrome Clinical Question: Do antidepressant medications improve irritable bowel syndrome (IBS) symptoms? Bottom Line: Both tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) may improve overall IBS symptoms. About 55% of patients treated with TCAs or SSRIs will benefit compared to ~35% with placebo. Only TCAs improve abdominal pain for ~60% of patients compared to ~30% with placebo. TCA

2020 Tools for Practice

7. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1)

is a first-in-class, minimally absorbed, small-molecule inhibitor of the gastrointestinal sodium/hydrogen exchanger isoform 3. This phase 3 trial assessed the efficacy and safety of tenapanor 50 mg b.i.d. for the treatment of patients with constipation-predominant irritable bowel syndrome (IBS-C). Methods: In this phase 3, double-blind study (ClinicalTrials.gov identifier ), patients with IBS-C were randomized to tenapanor 50 mg b.i.d. or placebo b.i.d. for 12 weeks followed by a 4-week randomized (...) Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1) Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History

2020 EvidenceUpdates

8. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study Full Text available with Trip Pro

in IBS. Larger, more rigorously conducted trials of FMT in IBS are needed. M El-Salhy et al. Expert Rev Gastroenterol Hepatol 12 (5), 439-445. May 2018. PMID 29493330. - Review Irritable bowel syndrome (IBS) is a widespread gastrointestinal disorder affecting 11.2% of the world adult population. The intestinal microbiome is thought to play a piv … Show more similar articles Associated data ClinicalTrials.gov/NCT03822299 Actions LinkOut - more resources Full Text Sources Medical Full-text links [x] [x (...) bacterial profiles changed also significantly in the groups received FMT. The FMT adverse events were mild self-limiting gastrointestinal symptoms. Conclusions: FMT is an effective treatment for patients with IBS. Utilising a well-defined donor with a normal DI and favourable specific microbial signature is essential for successful FMT. The response to FMT increases with the dose. Trial registration www.clinicaltrials.gov ( ) and www.cristin.no (ID657402). Keywords: colonic microflora; irritable bowel

2020 EvidenceUpdates

9. [Effect of healthy eating before intervention with a low FODMAP diet in pediatric patients with irritable bowel syndrome]. Full Text available with Trip Pro

[Effect of healthy eating before intervention with a low FODMAP diet in pediatric patients with irritable bowel syndrome]. Background: a diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) may be effective in the treatment of pediatric patients with irritable bowel syndrome (IBS). Its complexity and side effects make it a secondary therapeutic alternative. Objective: to demonstrate that nutritional education, aimed at optimizing the diet of children (...) with IBS, is able to improve gastrointestinal symptoms of children without following a diet low in FODMAP. Methods: prospective intervention study. Changes in gastrointestinal symptoms were analyzed by means of the Pediatric Quality of Life Inventory™ Gastrointestinal Symptoms (PedsQL™ GI Symptoms), after receiving nutritional education based on a healthy diet. Likewise, anthropometric changes and dietary habits were analyzed. Results: twenty-one patients were included (12 girls) with a mean age

2019 Nutricion hospitalaria Controlled trial quality: uncertain

10. Tenapanor (Ibsrela) - irritable bowel syndrome with constipation in adults

Tenapanor (Ibsrela) - irritable bowel syndrome with constipation in adults Drug Approval Package: IBSRELA U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: IBSRELA Company: Ardelyx, Inc. Application Number: 211801 Approval Date: 09/12/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF) (PDF) (PDF

2019 FDA - Drug Approval Package

11. Lyophilized versus Frozen Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection, Inflammatory Bowel Disease, and Irritable Bowel Syndrome: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Lyophilized versus Frozen Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection, Inflammatory Bowel Disease, and Irritable Bowel Syndrome: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Lyophilized versus Frozen Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection, Inflammatory Bowel Disease, and Irritable Bowel Syndrome: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you (...) need Lyophilized versus Frozen Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection, Inflammatory Bowel Disease, and Irritable Bowel Syndrome: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Lyophilized versus Frozen Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection, Inflammatory Bowel Disease, and Irritable Bowel Syndrome: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Last updated: August 14, 2019 Project

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

12. AGA Clinical Practice Guidelines on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D) Full Text available with Trip Pro

Summary of Recommendations of the American Gastroenterological Association on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults Statement Strength of recommendation Quality of evidence Recommendation 1: In patients presenting with chronic diarrhea, the AGA suggests the use of either fecal calprotectin or fecal lactoferrin to screen for IBD . Conditional Low Recommendation 2: In patients presenting with chronic diarrhea, the AGA suggests (...) Carrasco-Labra, A., Lytvyn, L., Falck-Ytter, Y. et al. AGA technical review on the evaluation of functional diarrhea and diarrhea-predominant irritable bowel syndrome in adults (IBS-D). Gastroenterology . 2019 ; 157 : 859–880 | | | | | 5 Traveler’s Health. Travelers’ diarrhea. Centers for Disease Control and Prevention website. ( Available at: ) Date accessed: January 27, 2019 | 6 Riddle, M.S., Connor, B.A., Beeching, N.J. et al. Guidelines for the prevention and treatment of travelers' diarrhea

2019 American Gastroenterological Association Institute

13. Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study Full Text available with Trip Pro

Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study Irritable bowel syndrome with diarrhea (IBS-D) is a functional gastrointestinal disorder with limited effective treatment options. We evaluated the efficacy and safety of eluxadoline in patients with IBS-D who reported inadequate symptom control with prior loperamide.Three hundred forty-six adults with IBS-D (Rome III criteria (...) ) were randomly assigned to placebo or eluxadoline 100 mg twice daily for 12 weeks. Patients recorded daily IBS-D symptoms, including worst abdominal pain (WAP) and stool consistency (through Bristol Stool Scale). The primary endpoint was proportion of composite responders, defined as patients who met daily composite response criteria (≥40% WAP improvement and <5 Bristol Stool Scale score) for at least 50% of treatment days, and recorded ≥60 days of diary entries over the 12-week period.Over 12 weeks

2019 EvidenceUpdates

14. Management of Irritable Bowel Syndrome (IBS)

Division of Gastroenterology, University of T oronto, T oronto, Ontario, Canada; 10 Division of Gastroenterology, Queen’s University, Kingston, Ontario, Canada Correspondence: Dr. Paul Moayyedi, BSc, MB, ChB, PhD, MPH, FRCP , FRCPC, AGAF, FACG, Director, Division of Gastroenterology, McMaster University, 1280 Main St. W . HSC 3V3, Hamilton, ON, Canada L8S 4K1, E-mail: moayyep@mcmaster.ca ABSTRACT Background & aims: Irritable bowel syndrome (IBS) is one of the most common gastrointestinal (GI) disorders (...) /gwy071 Original Article Downloaded from https://academic.oup.com/jcag/advance-article-abstract/doi/10.1093/jcag/gwy071/5290372 by guest on 22 January 2019Irritable bowel syndrome (IBS) is one of the most common gastrointestinal (GI) disorders. It is characterized by recurrent abdominal pain and altered bowel habits (i.e., constipation, diarrhea or both), often with associated bloating (1). Globally, IBS is estimated to affect about 10% of the general population, but prevalence rates are highly

2019 Canadian Association of Gastroenterology

15. Irritable bowel syndrome

be individualised and is dependent on the patient's predominant symptoms. Definition Irritable bowel syndrome (IBS) is a chronic condition characterised by abdominal pain associated with bowel dysfunction. The pain is often relieved by defecation and is sometimes accompanied by abdominal bloating. There are no structural abnormalities to explain the pain. IBS occurs in about 15% of the adult population. The aetiology is probably multi-factorial and evidence suggests motility, inflammatory, genetic, immune (...) , psychological, and dietary components. Drossman DA, Camilleri M, Mayes FA. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002 Dec;123(6):2108-31. http://www.ncbi.nlm.nih.gov/pubmed/12454866?tool=bestpractice.com History and exam presence of risk factors abdominal discomfort alteration of bowel habits associated with pain abdominal bloating or distension normal examination of abdomen passage of mucus with stool physical and sexual abuse age <50 years female sex previous enteric

2019 BMJ Best Practice

16. Irritable bowel syndrome: When should I suspect irritable bowel syndrome?

and management [ ] and expert opinion in review articles on irritable bowel syndrome [ ; ; ; ] and review articles on the Rome IV criteria for functional gastrointestinal disorders [ ; ]. CKS notes that the Rome IV criteria for the diagnosis of functional gastrointestinal disorders (which are predominantly used for clinical trials and research) have amended the criteria used to diagnose IBS [ ; ]. The term abdominal 'discomfort' is no longer included as a diagnostic criterion, as this is a non-specific term (...) Irritable bowel syndrome: When should I suspect irritable bowel syndrome? Diagnosis | Diagnosis | Irritable bowel syndrome | CKS | NICE Search CKS… Menu Diagnosis Irritable bowel syndrome: When should I suspect irritable bowel syndrome? Last revised in October 2017 When should I suspect irritable bowel syndrome? Consider the diagnosis of irritable bowel syndrome (IBS) in a person who has had any of the following symptoms for at least 6 months: Abdominal pain, or Bloating, or Change in bowel

2019 NICE Clinical Knowledge Summaries

17. Irritable bowel syndrome: What else might it be?

Irritable bowel syndrome: What else might it be? Differential diagnosis | Diagnosis | Irritable bowel syndrome | CKS | NICE Search CKS… Menu Differential diagnosis Irritable bowel syndrome: What else might it be? Last revised in October 2017 What else might it be? Alternative conditions which may present similarly to irritable bowel syndrome include: Malignancy (such as colorectal cancer, small bowel cancer, and lymphoma) — see the CKS topic on for more information. Other causes (...) of constipation, such as: Functional or drug-induced constipation — see the CKS topic on for more information. Hypothyroidism — see the CKS topic on for more information. Other causes of diarrhoea, such as: Inflammatory bowel disease — see the CKS topics on and for more information. Coeliac disease — see the CKS topic on for more information. Gastrointestinal infection and secondary lactose intolerance — see the CKS topic on for more information. Antibiotic-associated diarrhoea (for example Clostridium

2019 NICE Clinical Knowledge Summaries

18. Irritable bowel syndrome: Scenario: Management of irritable bowel syndrome

be individualized to the person's symptoms and psychosocial situation, and should initially include diet and lifestyle advice. Provide advice and reassurance about the diagnosis of irritable bowel syndrome, and offer sources of information and support, such as: The NHS patient leaflet . The gut and liver disease charity CORE (website available at ) provides support for patients and families and has a patient information leaflet . The IBS Network is a national charity supporting people living with irritable (...) physical activity, and encourage weight loss if the person is overweight or obese. See the CKS topic on for more information. Adults should aim to do 30 minutes of moderate intensity physical activity on at least 5 days of the week. Arrange to review the person, depending on clinical judgement, and if there are ongoing or refractory symptoms, consider further management options such as . Basis for recommendation The recommendations on the initial management of irritable bowel syndrome is largely based

2019 NICE Clinical Knowledge Summaries

19. Irritable bowel syndrome: Loperamide

Irritable bowel syndrome: Loperamide Loperamide | Prescribing information | Irritable bowel syndrome | CKS | NICE Search CKS… Menu Loperamide Irritable bowel syndrome: Loperamide Last revised in October 2017 Loperamide Loperamide is licensed for the symptomatic treatment of acute diarrhoea in irritable bowel syndrome (IBS). The recommended dose is: Initially 4 mg, followed by 2 mg for up to five days, dose to be taken after each loose stool; usual dose 6–8 mg daily; maximum 16 mg per day (...) . [ ] Contraindications and cautions Do not prescribe loperamide if the person has: Acute ulcerative colitis. Antibiotic-associated colitis. Conditions where abdominal distention develops. Conditions where inhibition of peristalsis should be avoided. Prescribe loperamide with caution if the person has: Hepatic impairment — due to reduced first-pass metabolism and the risk of hepatic accumulation. [ ] Adverse effects Possible adverse effects of loperamide include: Dizziness, headaches, flatulence, nausea. Abdominal

2019 NICE Clinical Knowledge Summaries

20. Irritable bowel syndrome: Linaclotide

Irritable bowel syndrome: Linaclotide Linaclotide | Prescribing information | Irritable bowel syndrome | CKS | NICE Search CKS… Menu Linaclotide Irritable bowel syndrome: Linaclotide Last revised in October 2017 Linaclotide Linaclotide 290 microgram capsules should be taken once daily, the dose to be taken at least 30 minutes before meals. [ ] Contraindications and cautions Do not prescribe linaclotide if there is suspected: Intestinal obstruction. Crohn's disease or ulcerative colitis (...) . Prescribe linaclotide with caution if there is: A predisposition to fluid and electrolyte disturbance. An increased risk of diarrhoea, for example with co-prescribing of nonsteroidal anti-inflammatory drugs (NSAIDs) or proton pump inhibitors. [ ] Adverse effects Possible adverse effects of linaclotide include: Abdominal distention, abdominal pain, diarrhoea, dizziness, flatulence. If diarrhoea is severe or prolonged, consider stopping treatment. Decreased appetite, dehydration, faecal incontinence

2019 NICE Clinical Knowledge Summaries